Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. recently completed a significant study titled ‘Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study – Kaiser Permanente Southern California.’ The study aimed to assess the effectiveness of two doses of the Pfizer-BioNTech BNT162b2 vaccine in preventing COVID-19-related hospitalizations. This research is crucial as it provides insights into the vaccine’s performance in real-world settings, helping guide public health decisions.
The study tested the Pfizer-BioNTech BNT162b2 vaccine, including its BA.4/BA.5 bivalent and XBB.1.5-adapted monovalent versions. These vaccines are designed to prevent COVID-19 and its severe outcomes, such as hospitalization and death.
This observational study employed a retrospective case-control design, focusing on patients’ past vaccination status and health outcomes. It aimed to determine the vaccine’s effectiveness against hospitalization, ICU admission, and other severe COVID-19 outcomes.
The study began on May 15, 2021, and was completed with the last update submitted on July 28, 2025. These dates are vital as they mark the study’s duration and the latest data available for analysis.
The completion of this study could positively impact Pfizer’s stock performance by reinforcing investor confidence in the vaccine’s effectiveness. It also positions Pfizer favorably against competitors in the COVID-19 vaccine market, potentially influencing industry dynamics.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.